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Introduction
Th   e original amyloid cascade hypothesis for Alzheimer’s 
disease (AD) [1] has recently been reformulated to focus 
on soluble aggregates as the pathogenic molecular form 
of the amyloid beta peptide (Aβ) [2] (Figure 1). Aβ is 
naturally present in the brain and cerebrospinal ﬂ  uid of 
humans throughout life [3]. Its role is currently unknown. 
Th   e mere presence of Aβ in the brain is not suﬃ   cient to 
cause symptoms of neurodegeneration. It has been 
recog  nized previously that neuronal injury is rather the 
result of ordered Aβ self-association [4]. Th  e amyloid 
plaques found in AD patient brains, which serve as a 
hallmark for AD, have been found to contain vast 
amounts of Aβ organized into amyloid ﬁ  brils. Th   ere is no 
clear correlation, however, between the presence of the 
Aβ containing plaques in the brain and the severity of the 
neurodegenerative symptoms observed in AD patients 
[5]. Th  erefore, the focus of research in this area has 
shifted from senile plaques toward soluble oligomeric 
conformations of Aβ as the toxic species as these strongly 
correlate with the severity of dementia [2,6,7]. Th  is 
oligomeric form of Aβ is highly toxic to the brain and is 
the trigger for loss of synapses and neuronal damage 
[8,9]. Because of this, many laboratories have been hunt-
ing for a speciﬁ  c molecular assembly of deﬁ  ned size that 
is the main trigger of AD. Th  e result has been the 
identiﬁ   cation of a host of molecular species of Aβ, 
ranging from dimers [10-12], trimers [13] and Aβ species 
with a molecular weight of 56 kDa [14] to Aβ-derived 
diﬀ  usible ligands (ADDLs) [15,16] and protoﬁ  brils [17] in 
potent neurotoxic fractions. All are capable of impairing 
memory formation in mice and their formation and 
signiﬁ   cant accumulation in the brain should thus be 
considered a potential cause of AD.
Recent in vitro studies of the amyloid formation of Aβ 
demonstrate that the species mentioned all occur but 
that they are only transiently populated [18-21]. More-
over, their isolation and characterization are hampered 
by solvent extraction procedures and detection methods 
[22,23], making it diﬃ     cult to study them in detail. 
However, looking at the studies available, a hypothesis 
can be formed that the key determinant for the neuro-
toxicity of Aβ not only involves the degree of oligo-
merization, but also the speciﬁ  c structural conformation 
of peptides in the assembly. Th   is concept reconciles the 
apparently contradictory results that widely diﬀ  ering 
preparations of Aβ exert similar cytotoxic eﬀ  ects, and 
oﬀ   ers the therapeutic potential for targeting the key 
conformation with small molecules or mono  clonal 
antibodies. Th   is review will discuss the degree to which a 
speciﬁ  c conformation rather than a speciﬁ  c oligomer size 
may act as the key determinant of development of AD.
The aggregation pathway of Aβ
Since the establishment of the amyloid cascade hypothe  sis, 
signiﬁ   cant research eﬀ   ort has been focused on the 
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be related to AD. In spite of this, it remains unclear exactly 
what happens to Aβ in vivo after it is cleaved from the 
amyloid precursor protein by γ-secretase. It is known that 
the carboxy-terminal heterogeneity generated by 
γ-secretase may be an important contributing factor since 
in vitro preparations of the two major peptide fragments 
generated, Aβ1-42 and Aβ1-40, display a marked diﬀ  erence in 
neurotoxicity by a range of biophysical assays and this 
correlates with a clear diﬀ  erence in aggregation behavior 
[24]. For example, samples of synthetic Aβ1-40 primarily 
exist in vitro as a monomer/dimer mixture, whilst from the 
time of preparation (time zero) samples of Aβ1-42 also 
contain a range of other low-order oligomeric species [7].
Th   e assembly of mature Aβ amyloid ﬁ  brils is generally 
described as a nucleation-dependent polymerization 
reac  tion. Like any chemical process, the characterization 
of this assembly process requires the description of the 
order in which the relevant molecular species occur 
along the reaction pathway. However, as aggregation is a 
stochastic process, molecules will not synchronize during 
the reaction and, as a result, the reaction mixture will be 
highly complex and composed of several species at any 
given time. Homogeneity of the sample is not thought to 
occur until after the polymerization reaction is complete 
and even then it is possible that the formed mature ﬁ  brils 
or plaques are not eternally stable. To make matters 
worse, the composition of the reaction will be signiﬁ  -
cantly modulated by peptide concentration and physico-
chemical parameters, such as temperature, ionic strength 
and pH. It is thus not surprising that indepen  dent studies 
of this highly dynamic reaction mixture have yielded a 
plethora of transient molecular species that have been 
claimed to occupy an essential position along this path-
way. Th   e transient nature of the intermediate oligomers is 
equally challenging for the characterization of the toxic 
potential of these species [25], and thus a number of 
diﬀ   erently sized oligomers have been suggested as the 
cause of AD (reviewed in [26-28]).
In general terms, the kinetics of ﬁ  bril formation by Aβ, 
as well as many other disease-related and synthetic 
amyloidogenic peptides, consists of a lag phase, during 
which a thermodynamically stable nucleus needs to 
accumulate, which is then followed by a rapid elongation 
phase that sees the formation of mature amyloid ﬁ  brils 
[29]. However, on a structural level there is signiﬁ  cant 
debate over which conformational changes are essential 
for the timing of the reaction. Most proposed pathways 
for the initial stages of Aβ amyloid ﬁ  bril  formation 
amount to a sequence of events that can be summarized 
as follows: unordered monomeric Aβ in solution converts 
into an ‘activated’ monomer that then recruits other Aβ 
molecules to form low-n oligomers [30].
Several studies proposed that monomeric Aβ in 
solution exists in an equilibrium between an α-helical 
and a β-sheet conformation (step I in Figure 2) and from 
this mixture only the β-sheet conformer can accom-
modate the formation of low molecular weight, β-sheet-
enriched oligomers (step II in Figure 2) [31,32]. In sharp 
contrast, other reports suggest that the conformation of 
Aβ in the activated monomeric state involves α-helical 
components [33]. Interestingly, the ambiguity between α-
helical and β-sheet propensities is a suﬃ   ciently frequently 
occurring feature of amyloid forming sequences that it 
can be employed to identify such sequences [34,35]. 
Moreover, helix-helix associations have been proposed to 
constitute the major mode of early associations between 
proteins en route to amyloid formation. Apart from Aβ, 
other well-known examples displaying similar charac  ter-
istics include islet amyloid polypeptide, α-synuclein and 
calcitonin [33]. Th  is helix association pathway would 
require an as yet undeﬁ  ned rearrangement of the initial 
helical species into a β-sheet conformation, but is sup-
ported by a range of nuclear magnetic resonance (NMR) 
studies of the solution structure of Aβ that report an α-
helical structure for the monomeric peptide.
It has to be noted that most of these studies were done 
in the presence of organic solvents and detergents that 
were intended to reduce the peptide’s aggregation rate 
suﬃ     ciently to allow the recording of NMR spectra. 
Figure 1. The reformulated amyloid cascade hypothesis 
by Hardy and Selkoe [2] to include oligomeric species. This 
hypothesis suggests a sequence of pathological events leading to 
Alzheimer’s disease. It further includes caspase 3 as a potential link 
between amyloid beta peptide (Aβ) and tau [129].
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in the presence of lipid membranes have reported 
increases in both α-helical [36] and β-sheet structures 
[37]. It is generally known that some detergents and 
organic solvents can induce secondary structure in 
proteins, particularly α-helical structure (reviewed in 
[38]). Yet, two carefully conducted studies employing 
solution NMR and molecular dynamics without the use 
of organic co-solvents and detergents failed to detect 
signiﬁ  cant α-helical stabilization for Aβ [39,40].
Whether signiﬁ  cant stabilization and population of such 
an intermediate is indeed required to trigger toxic 
oligomer formation can be debated. To illustrate this, it 
has been shown for both HypF-N and human lysozyme 
that aggregation can be initiated by a population of less 
than 1% of a speciﬁ  c partially folded conformation [41,42]. 
Small and only transiently populated confor  ma  tions hence 
could provide the key to toxic oligomer formation. 
Nevertheless, the conﬂ  icting nature of pub  lished reports 
on the conformational bias in monomeric Aβ suggests 
several aggregation-prone conformations may coexist and 
that environment heavily inﬂ   uences the route taken by 
most of these molecules. Moreover, post-translational 
modiﬁ   cations and the terminal hetero  geneity that 
characterizes Aβ in vivo may play a dominant role.
Whatever the conformations that drive the initial 
associations of Aβ peptides, the resulting low-n oligo-
mers seem to be consistently enriched in β-sheet 
structures, although the topology of the strands remains 
unresolved: some groups report that oligomers contain 
exclusively antiparallel β-sheet structure (step III in 
Figure 2) [43], whereas others suggest a mixture of anti-
parallel and parallel β-sheets [44]. Structural investigation 
of the Aβ aggregation pathway has suggested that anti-
parallel structures need to convert to a parallel topology 
in order to allow formation of the so-called protoﬁ  brillar 
state of Aβ (step IV in Figure 2), which is the individual 
building block of the amyloid ﬁ  brils and is thought to 
consist of a single array of peptides in a parallel β-sheet 
like conformation [11].
Th  e length-wise association of individual protoﬁ  brils 
produces the mature amyloid ﬁ  brils, whose structure has 
been studied in most detail due to their high stability 
under a wide range of physicochemical conditions (step 
Figure 2. Aggregation scheme of amyloid beta peptide involving the transformation of monomeric amyloid beta peptide through a 
variety of toxic oligomeric stages to a mature fi  bril. The arrow at the bottom shows the toxic timeframe derived from publications. The scheme 
has been adapted from Bartolini and colleagues [31]. Step I describes the equilibrium of the amyloid beta peptide (Aβ) monomer between random 
coil, α-helix and β-sheet. The β-sheet structured Aβ molecule has been adapted from Lührs and colleagues [45] (PDB structure 2BEG) and the 
α-helix-containing Aβ molecule has been modifi  ed from Sticht and colleagues [130] (PDB structure 1AML) using molecular dynamics with Yasara to 
obtain the given presentation [131].
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derived using solution NMR with hydrogen-deuterium 
exchange and mutagenesis suggests that residues 18 to 42 
stack as β-hairpin-like structures along the ﬁ  ber axis [45]. 
Although there is an ongoing debate on the exact 
involvement of particular residues in this arrangement 
(in particular the location of the loop), there seems to be 
general agreement that the amyloid ﬁ  brils that accumu-
late in plaques found in the brains of patients with AD 
are stabilized by a backbone of two intermolecular 
parallel β-sheets connected by a loop region [46].
In Figure 2, we show a schematic outline of the current 
known aspects of the ﬁ  brillation mechanism of Aβ, based 
on a recently published scheme by Bartolini and colleagues 
[31]. It remains unclear how oligomer size corresponds to 
conformational reorganization or how oligomer size and 
conformation combine to yield a toxicity response.
Does the size of Aβ oligomers determine 
neurotoxicity?
Th  e search for an Aβ species that is capable of causing 
cognitive disorder as observed in AD patients led to 
several reports of animal-cell derived [13,47,48], human-
derived [10] and synthetically prepared [9,49-52] oligo-
mers that have been found to induce disruptions of 
synaptic activity in vitro or impair cognitive function in 
animal models. For extensive reviews on these species 
see [26,27,53].
Monomeric and fi  brillar Aβ
Monomeric forms of Aβ have frequently been proposed 
as toxic modulators in the development of AD. For 
example, Taylor and colleagues [30] reported that maxi-
mum cell damage observed in SH-EP1 cells and hippo-
campal neurons using a SYTOX Green assay coincides 
with the accumulation of a monomeric Aβ species able to 
multimerize into higher-n Aβ species, also called ‘acti-
vated monomer’. Similarly, mature Aβ ﬁ  brils have been 
suggested as potent neurotoxic AD-inducers, although 
with similar inconsistent ﬁ  ndings as for mono  meric Aβ. 
Th   e hypothesis that not all ﬁ  bril morphologies are equally 
toxic, leading to variable results with regard to cyto-
toxicity, was successfully challenged by Yoshiike and 
colleagues [54]. Th  ey reported that, using point muta-
tions and chemical modiﬁ  cation, both a β-sheet ﬁ  brillar 
structure as well as the surface physicochemical compo-
sition of the ﬁ  bril deﬁ  ne the toxic potency of Aβ. One 
year earlier, Puzzo and Arancio [55] had shown that syn-
thetically derived ﬁ  brillar Aβ can impair the late phase of 
long-term potentiation. As it is very diﬃ   cult to ensure 
the purity of a monomeric or ﬁ  brillar Aβ solution, with-
out contamination of either preseeds or protoﬁ  brillar 
material, it can not be excluded that the toxicity observed 
for monomeric and ﬁ  brillar Aβ is actually the result of 
contamination. Moreover, increasing evidence suggests 
that the toxicity of Aβ originates instead from oligomeric 
Aβ, for which reason this review will further focus on the 
role of oligomeric Aβ in the development of AD.
The synaptotoxic SDS-stable dimer
In 2008, the Walsh lab identiﬁ  ed an enrichment of sodium 
dodecyl sulfate (SDS)-stable Aβ dimers in both human AD 
patients and rat cerebrospinal ﬂ  uid (CSF) [10] that activate 
glial cells and can lead to nerve cell death in cultures 
containing astrocytes [56]. Injection of human CSF 
containing Aβ dimers but not higher-n Aβ oligomers into 
animals showed a complete abolishment of long-term 
potentiation (Figure 3e); this adverse eﬀ  ect  could  be 
reversed by the systemic infusion of the synthetically 
derived anti-Aβ1-40 polyclonal antibody R1282. CSF 
samples that contained only Aβ monomer and no 
detectable dimer did not inhibit long-term potentiation. 
At this time it was also recognized that the isolation of 
large quantities of the SDS-stable dimer from human CSF 
was diﬃ   cult, and a synthetic, disulﬁ  de stabilized Aβ dimer 
(Aβ1-40Ser26Cys) was prepared [57] and used to further 
explore any detrimental eﬀ  ects of Aβ dimers on synaptic 
activity [11]. Later studies [12] used a combined approach 
of immunoblotting and western blotting tech  niques to 
study the Aβ population in J20 mice carrying Swedish and 
Indiana mutations in amyloid precursor protein. Th  ese 
studies showed that before SDS-stable dimers can be 
detected, Tris-buﬀ   ered saline and triton-insoluble Aβ 
aggregates are present, suggesting that the assembly of Aβ 
species throughout life is dynamic and heterogeneous. Th  e 
authors further concluded that it would be diﬃ   cult  to 
attribute synaptotoxicity to one single Aβ species.
Toxic Aβ*56
In 2006, the Ashe lab reported that the presence of an 
extracellular, soluble Aβ1-42 species with a molecular 
weight of 56 kDa (Aβ*56) coincides with memory loss of 
Tg2576 mice and that administration of an isolated 
fraction of Aβ of this molecular weight induced similar 
memory loss in young rats [14] (Figure 3c). Interestingly, 
this much larger 56 kDa species results in a similar AD-
like phenotype to that occurring with the dimer des-
cribed by the Walsh lab, suggesting that AD-related 
toxicity is extended over a very wide range of Aβ 
oligomer sizes. A recently published work systematically 
com  paring the eﬀ   ects of brain- or cell-derived Aβ 
assemblies with synthetic preparations further corro  bor-
ated a concentration-dependent detrimental eﬀ  ect  of 
Aβ*56 oligomers on cognition in rats [58].
Lipid-dissociated mature fi  brils
In 2008, work by our own group suggested that mature 
ﬁ  brils may not be the inert end-products of a pathway 
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Page 4 of 14Figure 3. Amyloid beta peptide is (synapto)toxic over a wide range of sizes. (a) Lipid-derived amyloid beta peptide (Aβ) oligomers cause 
learning and memory impairments in mice. Passive avoidance test of mice injected with backward protofi  brils. Light-dark step through test 
showed latency of entrance during the training accompanied with electrical shock (white bars) and during the testing 24 hours later (black bars). 
Injection of Aβ fi  brils/brain total extract (BTE) mixture-soluble fractions 1.5 hours before the shock impaired memory in contrast to groups injected 
with control vehicle. From Martins and colleagues [59]. (b). Soluble Aβ extracted from Alzheimer’s disease (AD) brain alters hippocampal synapse 
physiology and learned behaviour. Rats receiving AD Tris-buff  ered saline (TBS; dashed line) had a signifi  cantly shorter mean escape latency than 
animals receiving immunodepleted AD TBS (continuous line) at 48 hours after training. From Shankar and colleagues [11]. (c) Eff  ects of purifi  ed 
brain Aβ*56 (soluble Aβ species with an apparent molecular weight of 56 kDa) on memory of young rats. Aβ*56 impairs spatial memory. Rats that 
received vehicle but not Aβ*56 injections showed a signifi  cant spatial bias for the escape location 24 hours after training [14]. (d) Vulnerability of 
NT2 cells to soluble oligomeric Aβ in vitro. The ability of cells to oxidize MTT was used as a measurement of cell viability after treatment with Aβ. 
Cells were incubated in the presence of diff  erent concentrations of either Aβ or equivalent amounts of dimethyl sulfoxide (DMSO) control for 20 
hours. The x-axis represents the concentration of soluble oligomeric Aβ. The y-axis represents the percentage of viability of cells compared with 
the DMSO control. From Kim and colleagues [68]. (e) Human cerebrospinal fl  uid (huCSF) containing clearly detectable Aβ dimers disrupts synaptic 
plasticity in vivo. Samples of huCSF containing Aβ dimers (huCSF D) completely inhibited long-term potentiation, and this inhibition was prevented 
by previous immunodepletion of Aβ. Untreated huCSF (open circles), and immunodepleted samples (fi  lled circles) were injected 10 minutes before 
high-frequency stimulation (arrow). From Klyubin and colleagues [10]. ADDL, Aβ-derived diff  usible ligand; EPSP, excitatory postsynaptic potential. 
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Page 5 of 14involving the formation of a heterogeneous population of 
transient toxic Aβ oligomeric species [59]. We found that 
co-incubation of mature Aβ ﬁ   brils with biomimetic 
mem  brane particles results in the release of toxic Aβ 
oligomers, suggesting a ﬁ  bril to oligomer pathway. Incu-
bation of released Aβ oligomers from ﬁ  brils on hippo-
campal primary neuronal cell cultures resulted in 
profound cytotoxicity, and animals injected with these 
oligomers showed signiﬁ  cant cognitive decline compared 
with control animals (Figure 3a). Th  e main question 
arising from these observations is whether this ﬁ  bril to 
oligomer pathway might occur in vivo. Nevertheless, it 
has been reported that secondary lipid metabolic dis-
orders, such as hypercholesterolemia [60,61] or deregu-
lation of sphingolipid metabolism [62], frequently co-
occur with a diagnosis of AD. An interesting link with 
regard to this is the established fact that the ε4 allele of 
the gene encoding apolipoprotein, a cholesterol-carrying 
protein, has been deﬁ  ned as the major risk factor for AD, 
while the ε2 allele is protective [63,64]. An extensive 
review on the role of the apolipoprotein E allele type on 
progress of AD has appeared recently [65]. Th  e  relevance 
of such an apolipoprotein E allele type in the lipid-induced 
dissociation mechanism leading to sporadic forms of AD 
as well as the precise contribution of lipid-induced Aβ 
ﬁ   bril dissociation and the link with apolipoprotein E 
phenotype in vitro remain to be conﬁ  rmed.
Aβ-derived diff  usible ligands
In 1994 Oda and colleagues [66,67] ﬁ  rst mentioned that 
incorporation of clusterin (apoJ) into an Aβ1-42 solution 
inhibited mature ﬁ  bril formation but stabilized a slowly 
sedimenting Aβ1-42 aggregate. Aggregates formed accord-
ing to this protocol are resistant to low concentrations of 
SDS (prepared in the presence of clusterin (apoJ)) and 
enhance oxidative stress in PC12 cells. A similar aggre-
gating species can also be formed in the absence of 
clusterin by employing cold-induced aggregation [9]. 
Th   ese so-called ADDLs potently disrupt long-term 
potentiation in hippocampal slices from young adult rats 
at very low concentrations [9], reduce cell viability in a 
range of diﬀ  erent cell lines [68] (Figure 3d) and were 
found to alter cell viability by aﬀ  ecting membrane thick-
ness and inducing overall ionic leakiness [69]. Structural 
characterization revealed that ADDLs are small (approxi-
mately 4.8 to 5.7 nm), soluble globular structures [9,70] 
with an estimated mass of 17 to 42 kDa (derived using 
atomic force microscopy (AFM)) [9] that migrate during 
SDS gel electrophoresis to 17 kDa and 27 kDa, with the 
latter being the predominant species [9]. Th  e very low 
concentration required for a toxic response led to the 
hypothesis that ADDL-induced toxicity may be speciﬁ  c 
and it was postulated that such toxicity might involve 
speciﬁ  c cell-surface receptors [9,68].
Protofi  brils
Aggregation kinetics of Aβ1-40 and Aβ1-42 were investigated 
by Harper and colleagues [18] and Walsh and colleagues 
[21] using AFM. Th  ese studies detected curvilinear, 
soluble assemblies, termed protoﬁ  brillar aggregates, which 
appeared to be intermediates on the pathway to amyloid 
ﬁ  bril formation. Th   eir transient and intermediate nature 
was conﬁ  rmed by the ﬁ  nding that these aggregates grow 
slowly at ﬁ  rst and then rapidly disappear in favor of the 
formation of mature amyloid ﬁ   brils [18]. Th  eir 
involvement in disease was derived from size exclusion 
chromatography experiments showing that Aβ1-42 and 
Aβ1-40 E22Q (later called the ‘Dutch’ mutation), accu-
mulate more protoﬁ  brils compared with wild-type Aβ1-40 
[13], and they were found to inhibit memory formation in 
animals [11] (Figure 3b). Morphological characterization 
of these protoﬁ  brillar structures by AFM, transmission 
electron microscopy, quasielastic light scattering and size 
exclusion chromatography revealed that these curvi-
linear, soluble assemblies have an apparent mass of 
>100  kDa, a diameter of 6 to 8 nm, and a length of 
≤200 nm [21].
Cytotoxicity and neurotoxicity as parameters for 
development of AD - practical considerations
Extraction procedures
Th   e wide variety of transient and intermediate Aβ species 
on the pathway to ﬁ   bril formation (dimers, trimers, 
higher n-mers, protoﬁ  brils) that have been detected by 
several studies over the years have all been found to exert 
toxicity on cells in a manner that supposedly causes AD 
(Figure 3). Interestingly, Bernstein and colleagues [71] 
showed by using ion mobility spectroscopy coupled with 
nanoelectrospray mass spectrometry that Aβ1-42 can 
spon  taneously co-exist as monomeric or as large oligo-
meric aggregated species. Th  ese large species rapidly 
developed into large aggregates. However, ﬁ  ltration 
employed to remove large species resulted in the 
formation of small oligomers that did not convert into 
large aggregates rapidly.
Various subﬁ   brillar Aβ-derived toxins have been 
detected in vivo [72-74] and these all correlate well with 
brain dysfunction and degeneration observed in both 
transgenic mice and humans [7,75]. Th  e extraction and 
analysis procedures used to study these Aβ fractions 
involve methods that have been established to dissociate 
or, at least, destabilize ﬁ   brillar proteins and include 
homogenization, addition of SDS, β-mercaptoethanol or 
urea and boiling [7,75]. Th   erefore, it is not clear whether 
any of these species really occur in the diseased brain.
Another approach, involving the preparation of oligo-
meric Aβ from a synthetic source and subsequent 
evaluation of their impact on synaptic activity or cyto-
toxicity has proven a valuable approach to circumvent 
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vivo occurring Aβ. A recent publication by Reed and 
colleagues [58] compares the eﬀ  ects of Aβ derived from 
synthetic sources, transfected cells and mouse or human 
brains. Cognitive eﬀ  ects were studied using the Alter  na-
ting Lever Cyclic Ratio cognitive assay upon intra-
ventricular injection with Aβ from various sources into 
rat brains and it was found that Aβ oligomers from all 
sources are potently able to induce cognitive defects.
The detection of toxic Aβ assemblies by A11 antibody
Th   e mature ﬁ  brillar form and monomeric Aβ have both 
been conﬁ  rmed on many occasions as the only non-toxic 
species. Moreover, co-incubation with the toxic-confor-
mation-recognizing antibody A11 suppresses the toxic 
eﬀ  ect of Aβ oligomers, suggesting that, even though these 
Aβ species vary widely in size and shape, there must be a 
common denominator to their toxic origin. Even more 
interestingly, many proteins, either disease-related or non-
disease-related, have been found to undergo a speciﬁ  c 
conformational transition that is toxic to cell cultures and 
is A11-reactive [19,76]. However, A11 reactivity as such 
does not always correlate well with the potency of Aβ 
assemblies to induce toxicity, as was reported recently by 
Noguchi and colleagues [77]. Th   ese researchers isolated 
an A11-negative fraction of Aβ from brains inﬂ  icted by 
AD or dementia with Lewy Bodies morphologically 
appearing as a 10- to 15-nm spherical Aβ species and 
reproduced these structures using synthetic Aβ. Both 
assemblies induced damage to human neuronal cells and 
mature rat hippocampal neurons, and these Aβ species 
were assigned a role in disturbing presynaptic signaling 
mechanisms [77]. It appears that even though it is 
potentially useful for preliminary screening for toxic 
potency, A11-negativity does not exclude the possibility 
of Aβ assemblies playing a major role in the disease 
mechanism of AD. It is hence advisable to combine 
studies using the A11 antibody with complementary 
results on the neurotoxicity of detected or isolated Aβ 
species.
The complex cellular environment
An important discussion that tightly links into the ﬁ  eld of 
deﬁ  ning the most toxic species of Aβ is that on deﬁ  ning 
to what extent cytotoxic and neurotoxic results actually 
represent in vivo pathophysiological mechanisms leading 
to AD. A wide range of results are used to assay for the 
eﬀ  ects of Aβ on (neuronal) cells, which can be divided 
into experiments probing for general cytotoxic, and more 
speciﬁ  c neurotoxic deviations. For example, assays that 
exclusively evaluate the cytotoxic eﬀ  ects of Aβ species 
largely ignore subtle changes that have been shown to 
occur in the metabolism and functional output of 
neuronal cells prior to overt cell death (reviewed in [78]). 
Aβ is known to be a dynamic molecule, converting from 
monomeric through a number of lesser-deﬁ  ned oligo-
meric stages to mature plaques; as a consequence, time 
points at which cytotoxicity is observed do not reﬂ  ect the 
initial stages of the damage Aβ inﬂ  icts.
A further complication with regard to neurotoxic 
results is that the actual initial stages of the disease are 
not known and have been reported to involve, for 
example, microglia cells of other than neuronal origin 
(reviewed in [79]). An elaborative review on the toxic 
eﬀ  ects of Cu/Zn superoxide dismutase (SOD1), impli-
cated in amyotrophic lateral sclerosis, illustrates how the 
protein can aﬀ  ect multiple cell types in a highly complex 
manner which, judging from the complexity of the brain 
anatomy as well as the diﬃ   culty in developing a treatment 
and pinpointing the actual triggers for onset of AD, may 
well be applicable to AD as well [80].
Th  ese ﬁ  ndings suggest that one single result does not 
necessarily embrace all the facets involved in the develop-
ment of AD and underlines the necessity to employ a 
multidisciplinary approach, including assays to report on 
the early eﬀ   ects (for example, long-term depression 
(LDP) or synaptic activity read-outs) and late eﬀ  ects 
(cytotoxic eﬀ  ects) of Aβ on a cellular level as well as, for 
example, cognition assays to evaluate the progress of the 
condition overall. It further implies the importance of 
investigating the continuity of the disease in terms of 
time lines of appearance of speciﬁ   c symptoms and 
cellular eﬀ   ects rather than a single time point or Aβ 
species. A publication that illustrates the dynamic eﬀ  ects 
of Aβ toxicity rather well shows that Aβ-mediated 
neuronal cell death is a dynamic process, depending on 
the progress of the aggregation pathway of Aβ, rather 
than a stable situation [81].
Analyses for AD-linked pathophysiology: the MTT assay
It is worth mentioning some issues with regard to the 
actual measurement of the potency of Aβ species to 
induce potentially pathophysiological eﬀ   ects in AD 
models. A frequently used assay for this purpose is the 
MTT assay, which is based on the conversion of yellow 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (a tetrazole) into purple insoluble formazan. Th  e 
formazan compound is subsequently solubilized by a 
solubilization solution and the absorbance of soluble 
formazan can be measured spectrophotometrically [82]. 
Th  e reduction reaction to formazan can, however, be 
aﬀ  ected by Aβ in the absence of cell death [83-85]. A 
number of potential reasons for this eﬀ  ect have been 
discussed by Wogulis and colleagues [81] and range from 
variations in formazan crystal morphology, exocytosis of 
MTT formazan, MTT-induced interaction of Aβ with 
intracellular targets and eﬀ  ects of Aβ on the neuronal 
membrane.
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A further discrepancy that is frequently highlighted in 
the literature is the observation that often non-physio-
logically related and excessive concentrations of in vitro 
prepared Aβ are required to observe detrimental eﬀ  ects. 
For example, in cell cultures Aβ usually needs to be added 
in the micromolar range for eﬀ  ects to be observed, while 
physiological concentrations of Aβ in vivo are estimated 
to be in the nanomolar range. One recent publication 
provides a potential answer to this question by showing 
that Aβ can be taken up by neuronal-like cells but not 
neuron-unrelated kidney cells. Upon uptake, Aβ can 
accumulate in late endosomes or lysosomes, where Aβ 
concentrations of up to 2.5 μM can be reached. At such 
elevated concentrations Aβ was found to form high 
molecular weight Aβ assemblies and these assemblies 
can, in turn, seed amyloid ﬁ  bril formation [86].
Toxic species or building block?
It is entirely possible that all the preparations mentioned 
in the previous paragraphs are uniﬁ  ed by a highly potent 
neurotoxic Aβ assembly of well deﬁ   ned size that is 
present at concentrations that preclude direct detection 
but mediate toxicity eﬀ   ectively, and that this elusive 
species is the cause of AD. However, it is more likely that 
a wide range of Aβ oligomers are toxic. Given that the 
reaction mixture is highly heterogeneous, the puriﬁ  ed 
species is an almost arbitrary result of the conditions 
chosen to enrich the fraction and the method employed 
to establish a size estimate. Th  e apparent molecular 
weight of a particular fraction is usually estimated from 
its elution proﬁ  le from matrix-assisted molecular sieving 
techniques, such as gel electrophoresis and size exclusion 
chromatography, often carried out in the presence of low 
concentrations of SDS (0.1%). In order to arrive at a 
molecular weight estimate, the mobility of the oligomeric 
fraction needs to be compared to those of other proteins 
and peptides that act as molecular weight standards. 
Th  ere are several problems with this approach. First, in 
the absence of even these low doses of detergent, the 
elution proﬁ  les show almost exclusively higher molecular 
weight assemblies, raising the question of whether the 
reported molecular size corresponds to the neurotoxin 
itself or merely to a stable fragment [22,23,87]. Second, 
comparison with migration proﬁ  les of reference proteins 
is not reliable for aggregating proteins that have a 
notorious feature that is systematically underestimated in 
the AD ﬁ   eld: amyloid ﬁ   brils and their precursors are 
employed in nature for their mechanical strength and 
high adhesiveness on a range of surfaces. Bacteria, for 
example, employ curli amyloids for adhesion to host 
organism tissues or to colonize a synthetic surface [88]. 
When such preparations are subjected to molecular 
sieving, they will hence be sorted by their aﬃ   nity for the 
matrix and resistance to the employed ﬂ  ow rate, thereby 
obliterating the main assumption required to use mole-
cu  lar sieving proﬁ   les to estimate size. When sample 
fraction  ation is achieved in detergent free buﬀ  ers, and 
the molecular weight is measured using an absolute tech-
nique, such as static light scattering, that does not require 
comparison of the migration rate through some chemical 
matrix, signiﬁ   cantly higher molecular weight species 
have been observed, both by us [59] and by others [89].
In conclusion, it remains unclear which of the species 
discussed above occurs as quasi-independent units in the 
brain of AD patients or if they are usually part of larger 
molecular assemblies. After all, the extraction procedures 
used may importantly aﬀ   ect the Aβ species obtained, 
which might not necessarily reﬂ  ect those involved in the 
development of AD. One apparent conclusion that can be 
drawn is that the toxic form is neither monomeric nor 
ﬁ  brillar, and that the toxic species is a soluble form of Aβ. 
As oligomer size does not correlate tightly with the 
progression of AD, it seems likely that the toxic behavior 
can be induced by factors other than oligomer size alone.
The structural requirements of a neurotoxin
A complete overview of the pathways through which Aβ 
oligomers are thought to mediate toxicity falls well 
outside the scope of this article and these are reviewed 
extensively elsewhere [90,91]. However, we need to 
brieﬂ  y consider them here in order to understand the 
structural requirements for toxicity-mediating inter-
actions. It now seems that soluble Aβ oligomers do not 
aﬀ  ect the lifecycle of neurons in general but that the 
eﬀ  ect may be more speciﬁ  cally related to the interference 
of synaptic function, judging from the low eﬀ  ective 
dosage required to induce a toxic response [9], and more 
speciﬁ  cally, that Aβ oligomers interfere with the mach  i-
nery responsible for synaptic vesicle release at the pre-
synaptic terminal (for reviews see [53,92]).
Two major classes of mechanisms have been proposed 
to explain how Aβ oligomers interact toxically with the 
cell. One class is receptor-mediated interactions, such as 
the previously proposed interactions between receptor X 
and ADDLs [40], the interaction with N-methyl  D-
aspartate receptors [93,94] or the interaction with human 
prion proteins by the Strittmatter group [95]. Although 
the conformational requirements for receptor-mediated 
toxicity have not been extensively studied, we know from 
other protein-peptide interactions that structural 
require  ments are usually very speciﬁ  c [96]. Th  e second 
major group of toxic mechanisms involve some form of 
membrane disruption, which is also a much explored 
potential disease mechanism for several other amyloid-
oses (for a review see [97]), lending support to the idea 
that amyloid formation by any peptide sequence goes 
through a toxic intermediate structure. In fact, a common 
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Dobson and Stefani and colleagues [98] from toxicity 
studies of a range of amyloid ﬁ   brils, could be equally 
compatible with a receptor-mediated interaction, although 
the focus in this ﬁ  eld has been strongly on membrane 
disruption. Another strong line of support for the notion 
of a toxic conformation comes from the conformation-
speciﬁ  c antibody A11, which also recognizes several other 
amyloidogenic proteins and peptides that are known to 
form pore-compatible oligomers [19,99]. A recent review 
by Glabe [100] explores the concept of conformation-
dependent toxicity in more detail.
Th  e strong focus on the sizes of Aβ assemblies that 
display potency in the disruption of neuronal function 
may falsely give the impression that other structural 
aspects, like peptide conformation, are being neglected. 
However, when considering the possible molecular 
mechanisms by which the Aβ peptide exerts its toxicity, 
the conformation of the individual peptide in the 
molecular assembly is clearly a critical factor that needs 
to be carefully considered, and both receptor-mediated 
interaction and membrane disruption models impose 
speciﬁ   c structural requirements on the oligomers. 
Progress in this ﬁ  eld is slow, however, since techniques 
for studying peptide conformations suﬀ   er from the 
experimental diﬃ   culties of working with heterogeneous 
aggregating samples even more than molecular sizing 
techniques as they generally require higher peptide 
concentrations, further promoting aggregation.
Th   e seemingly conﬂ  icting results obtained by diﬀ  erent 
groups on the size requirements of the toxic Aβ oligomer 
could be elegantly uniﬁ  ed when a model is considered in 
which peptide oligomerization provides the necessary 
intermolecular interactions required to stabilize a toxic 
conformation that cannot be adopted by a monomer in 
isolation. In such a model any oligomer could be toxic as 
long as its constituent peptides are maintained by the 
intermolecular interactions in the appropriate confor  ma-
tion to mediate toxicity, rendering dimers as potently 
toxic as 12-mers or higher order oligomers. Th  e model 
would further predict that oligomerization is required 
per se (independent of exact size) and that a speciﬁ  c 
conformation needs to accumulate in the Aβ oligomer 
fraction in correspondence with toxicity.
Structural studies detect a specifi  c conformation of toxic 
oligomers
Substantial evidence supports the hypothesis that ﬁ  brillar 
Aβ is conformationally distinct from monomeric Aβ but 
the investigation into the speciﬁ   c structural transition 
states of Aβ along the pathway to mature ﬁ  brils has been 
hampered by the inability to arrest the transient Aβ 
oligomers in stable, intermediate conformations. A variety 
of spectroscopic techniques have shown that monomeric 
Aβ is disordered in aqueous solution, adopting some 
nonrandom, local conformations [101,102]; thus, it can 
be categorized as a ‘natively disordered’ protein, such as 
α-synuclein, which is implicated in Parkinson’s disease 
(for a review on natively disordered proteins see [103]). 
Solid-state NMR studies have revealed that Aβ ﬁ  brils are 
organized in a parallel β-sheet structure (for a review see 
[104]). Site-directed spin labeling showed that ﬁ  brillar 
core regions are composed of 20 amino acids or more 
(for a review see [105]) and the cores of most amyloid 
ﬁ  brils, including those composed of Aβ, have been found 
to assume a typical steric zipper conformation [106].
Th  e question that arises is: does unstructured Aβ 
directly transform into a well-organized ﬁ  bril or is/are an 
intermediate(s) involved? Moreover, how does such a 
transition in structure relate to the toxicity observed for 
oligomeric Aβ? A structural investigation using circular 
dichroism on the ﬁ  brillation pathway of Aβ1-40 by Walsh 
and colleagues [107] suggests that Aβ ﬁ   rst forms a 
transitory α-helical conformation and then transforms 
into a β-sheet characteristic for ﬁ  brillar Aβ. Accumula-
tion of early α-helical enriched intermediates has been 
reported before using in vitro experiments and molecular 
modeling [43,107-110]. Whether α-helix formation is 
relevant within the AD context or is on- [108] or oﬀ  -
pathway [111] has been an issue of debate. However, the 
fact that aggregation and toxic eﬀ  ects in cell culture and 
hippocampal slices are inhibited and that locomotor 
activity is improved and the lifespan prolonged in Droso-
phila melanogaster in the presence of ligands that bind to 
and stabilize a region in Aβ in an α-helical conformation 
[110] supports the on-pathway paradigm. Such an eﬀ  ect 
can be explained either by a neutralizing eﬀ  ect on toxic 
α-helical Aβ or, alternatively, by these inhibitors blocking 
earlier stages in the aggregation process that can lead to 
the formation of the actual toxic species. Th  e  occurrence 
of a kinetic intermediate composed of α-helical compo-
nents is not limited to Aβ but is also observed for a range 
of other peptides, such as insulin [112,113] and a model 
38-residue helix-turn-helix peptide, αtα [114].
Computational analysis of the ﬁ  brillation pathways of 
Aβ1-40 and familial AD-related mutations suggests that 
early events involve the formation of an ordered, cross-β-
structured nucleus composed of six to ten monomer 
chains [115]. Th  is supports an earlier proposition by 
Grant and colleagues [116] that the aggregate seed for Aβ 
involves a speciﬁ  c type of collapsed structure involving 
exposed β-strands. Th  e evolution of β-structure upon 
higher order oligomerization and ﬁ   brillation has been 
published many times using a range of spectroscopic 
techniques, including circular dichroism [31,107,108], 
ﬁ  ber X-ray crystallography [106] and Fourier transform 
infrared spectroscopy [32,43], and also by computational 
methods [109]. If both mature ﬁ   brils and growing 
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mines their diﬀ  erential toxic eﬀ  ects? Work by the group 
of Goormaghtigh has shown, using attenuated total 
reﬂ  ec  tion Fourier transform infrared spectroscopy, that 
an anti-parallel β-sheet conformation of Aβ distinguishes 
the oligomeric structure from the parallel β-sheet 
structure of mature ﬁ  brils [43]. Th   e experimental set-up 
used ensured careful preparation conditions for Aβ to 
obtain solutions enriched in either oligomeric or ﬁ  brillar 
Aβ. To support this suggestion, the work by Yu and 
colleagues [44] used NMR to show that oligomeric 
intermediate assemblies stabilized by the addition of 
detergents and fatty acids have a mixed parallel and anti-
parallel β-sheet structure that can alter synaptic activity. 
On a longer timescale this anti-parallel β-sheet rearranges 
into a less ﬂ   exible parallel β-sheet characteristic for 
ﬁ  brillar Aβ [43]. If the membrane-peptide interactions 
are indeed responsible for the onset of the cascade of 
toxic responses leading to cell death, then mutations in Aβ 
leading to early onset cases of AD should show considerably 
more pronounced interaction with membranes.
Conformational antibodies, β-sheet breaker compounds 
and mutation are eff  ective disruptors of Aβ toxicity
Th   e introduction of β-sheet breaking amino acids in the 
carboxyl terminus of Aβ1-42 [117-119], or co-incubation 
with β-sheet breaking compounds [120-123] or peptides 
[124] have been shown to be highly eﬀ  ective inhibitors of 
Aβ aggregation and to reduce toxic responses to Aβ in a 
neuronal cell culture [117,119]. Th   e relevance of β-sheet 
structure for toxicity has also been supported by the 
ﬁ  nding that many proteins respond to the conformation-
speciﬁ   c antibody A11 [19], including natively folded 
proteins not related to disease - for example, a GroEL 
oligo  mer complex, a bacterial chaperonin [76], heat 
shock proteins 27, 40, 70, and 90, yeast heat shock protein 
104 and bovine heat shock cognate 70 [76], but also 
trans  thyretin and α2-macroglobulin, both proteins asso-
ciated with aggregation themselves and found to have a 
β-sandwich topology [125-128]. Interestingly and analo-
gous to β-sheet breaker peptides,  co-incubation of Aβ 
and a range of other oligomeric aggregates from α-
synuclein, islet amyloid polypeptide, polyglutamine, 
lysozyme, human insulin, and prion peptide 106-126 with 
other A11-positive proteins has an anti-aggregation 
eﬀ  ect on Aβ [19] similar to co-incubation with A11 anti-
body [76] and limits toxicity in neuroblastoma SH-SY5Y 
cells as assessed by the 3-[4,5dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide reduction assay and lactate 
dehydrogenase release [19]. Moreover, recent work by 
Yoshiike and colleagues [76] has deﬁ  ned the epitope of 
the A11 antibody as the β-sheet edge of proteins. Th  e 
A11 antibody is reactive to the Aβ oligomer conformation 
over a wide timeframe and recognizes pentameric Aβ up 
to protoﬁ  brils [19]. Th  is  ﬁ  nding strongly suggests a struc-
tural similarity between all these species, which could be 
related to toxicity.
SDS-stable tetramers and dimers are not recognized by 
the A11 antibody [19] but still have been found to exert 
profound toxicity in cell culture [11,56]. However, extrac-
tion procedures to obtain dimeric and other low-n 
aggregated Aβ from tissue and neuronal cells that involve 
SDS or sonication could partly dissociate small oligomers 
into their basic building blocks. Th  ese  ﬁ  ndings show that 
toxic oligomeric Aβ, over a wide range of sizes, has a 
structure distinct from monomeric or ﬁ  brillar Aβ, which 
might provide the key to their toxic potential.
Conclusion
Th  e studies reviewed above highlight the challenging 
nature of identifying the critical component of the complex 
and constantly evolving reaction mixture that is the ageing 
Aβ peptide solution. However, the potential result will be 
highly rewarding as it will allow us to understand how 
known risk factors for AD map onto the formation of toxic 
intermediates of amyloid formation: do well established 
risk factors such as carboxy-terminal heterogeneity, the 
apolipoprotein E allele and age act by stabilizing the toxic 
substructures, and if so, which therapeutic interventions 
are best suited for counter  act  ing these eﬀ  ects? Moreover, 
as long as we cannot accu  rately model the accumulation of 
the neurotoxic species, we cannot be certain that 
therapeutic inter  vention will produce the desired outcome. 
For example, an overall decrease in the concentration of 
Aβ may stabilize low-n oligomers, thereby poten  tially 
increasing rather than decreasing toxicity.
In conclusion, a wide range of AD-related (synapto)
toxic Aβ oligomeric sizes have been identiﬁ  ed.  How 
oligo  mer size precisely relates to the disease process has 
not been clariﬁ  ed and recent work shows that the wide 
range of Aβ oligomers may have a speciﬁ  c conformation 
in common. Th  ese  ﬁ  ndings suggest that Aβ oligomer size 
may not be the only AD-inducing factor and we propose 
a new paradigm in which both oligomer size and struc-
tural arrangement act as toxic parameters in AD develop-
ment. Studies targeting the toxic contributor to AD in the 
past have usually highlighted only one of these aspects, 
but we suggest that further studies should employ a 
multi  disciplinary approach in which oligomer size, struc-
tural characteristics and synaptic activity results are 
recorded simultaneously over a long kinetic timeframe. 
Suﬃ   cient resolution in such a kinetic study should allow 
access to structural information on transient inter-
mediates, which may be further supported by employing 
means of stabilizing these species using cross-linking, 
conformation-sensitive antibodies or lipid-induced ﬁ  bril 
dissociation and by studying familial AD-related 
mutations in Aβ.
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